ARTICLE | Company News
Hangzhou Just licenses Lilly’s bone disease program
April 5, 2019 4:39 PM UTC
Transcenta Holding’s subsidiary Hangzhou Just Biotherapeutics gained exclusive greater China rights from Lilly to develop and commercialize a portfolio of biologics, including blosozumab, for bone disease.
Eli Lilly and Co. (NYSE:LLY) will receive an undisclosed upfront payment plus equity shares in Transcenta Holding Ltd., and will be eligible for undisclosed regulatory and sales milestones, plus royalties...